Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors who purchased Seres Therapeutics, Inc. (“Seres” or the “Company”) (NASDAQ: MCRB) securities between June 25, 2015 and July 29, 2016, inclusive (the “Class Period”). Seres investors have until November 28, 2016 to file a lead plaintiff motion.

Investors suffering losses on their Seres investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.

According to the complaint filed in this lawsuit, throughout the Class Period defendants issued false and misleading statements to investors that Seres Therapeutics advertised and hyped its lead drug product candidate SER-109 as “novel class of biological drugs” and a potential “first-in-field drug” despite knowledge that the Phase 2 clinical trial of SER-109 would fail to achieve its primary endpoint as compared to placebo. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you purchased shares of Seres during the Class Period you may move the Court no later than November 28, 2016 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161122005780/en/